Stifel Reiterates Buy Rating on Inhibrx Biosciences (INBX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
| (NASDAQ: INBX) | Delayed: 96.04 +7.43 (8.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $88.61 | 52 Week High | $ | |||
| Open | $88.52 | 52 Week Low | $ | |||
| Day High | $98.00 | P/E | N/A | |||
| Day Low | $88.52 | EPS | $ | |||
| Volume | 138,537 | |||||
